Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...

The Philippine Press Institute (PPI) together with Novartis held a hybrid seminar-workshop for journalists entitled “Anatomy ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Novartis has assured that steps are being taken to ensure the adequate supply of Desferal, a drug crucial for treating iron ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

肺移植行业报告对全球范围内重点竞争企业进行详尽分析，其中包括Terumo, Pfizer, Sanofi, Cleveland Clinic, Astellas Pharma, Novartis, Roche, Temple Lung Center, ...

Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...

Novartis announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible ...